Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.59 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.59 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.59 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.59 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.59 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819247 | 0.92 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8818830 | 0.90 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6123147 | 0.90 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9256307 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9257551 | 0.89 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8820003 | 0.88 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9258519 | 0.86 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8819599 | 0.86 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9263683 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8819929 | 0.84 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2011007819-A1 | PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND | 塩野義製薬株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | PSEN1 9/4885PSEN2 20/4885APH1B 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.